Ocugen Inc. (NASDAQ:OCGN) shares are down during Tuesday’s session following topline data from its Phase 2 ArMaDa trial of OCU410.

OCU410 is an investigational gene therapy for geographic atrophy (GA) secondary to dry age-related macular degeneration (dAMD).

The trial involved 51 patients aged 50 and older, randomized to receive either a medium or high dose of OCU410 or no treatment.

Efficacy Signals Remain, But Below Interim Trends

The optimal (mid-dose) cohort showed a 31% reduction in lesion growth versus control (p<0.05).

Treatment slowed ellipsoid zone (EZ) loss by 27%, suggesting preservation of photoreceptor structure linked to visual function.

55% of patients achieved over 30% lesion size reduction, versus the control.

Subgroup analysis (subjects with baseline GA lesions ≥5 mm2 and ≤17.5 mm2) showed 33% reduction in lesion growth compared to control in medium dose OCU410, with similar reductions in the high dose group.

Data released on Tuesday came lower than the interim data released in January.

Medium dose achieved 54% lesion reduction (p=0.02; N=10) vs. high dose 36% (p=0.05; N=8) compared to control.

Interim data showed a 46% lesion growth reduction (medium + high dose vs. control; p=0.015; N=23) at 12 months.

Phase 3 Timeline Remains On Track

Ocugen plans to initiate the OCU410 Phase 3 registrational trial in the third quarter of 2026 in line with the company’s goal of three BLA filings in three years.

Earlier, the company expected a Biologics License Application (BLA) filing for OCU410 in 2028.

Ocugen Technical Indicators Signal Mixed Momentum

Currently, Ocugen is trading 9.5% below its 20-day simple moving average (SMA) and 9.5% above its 50-day SMA, indicating mixed short-term momentum. Over the past 12 months, shares have increased 182% and are currently positioned closer to their 52-week highs than lows.

The RSI is at 54.98, which is considered neutral territory, suggesting that the stock is neither overbought nor oversold. Meanwhile, MACD is at 0.1624, below its signal line at 0.1668, indicating bearish pressure on the stock.

The combination of neutral RSI and bearish MACD suggests mixed momentum for Ocugen, indicating that traders should watch for potential shifts in direction.

  • Key Resistance: $2.00
  • Key Support: $1.50

Analyst Consensus & Recent Actions: The stock carries a Buy Rating with an average price target of $7.55. Recent analyst moves include:

  • Canaccord Genuity: Initiated with Buy (Target $12.00) (Mar. 17)
  • Oppenheimer: Initiated with Outperform (Target $10.00) (Mar. 11)
  • Chardan Capital: Buy (Maintains Target to $7.00) (Mar. 5)

Top ETF Exposure

  • Direxion Moonshot Innovators ETF (NYSE:MOON): 2.35% Weight

OCGN Stock Price Activity: Ocugen shares were down 11.48% at $1.85 at the time of publication on Tuesday, according to Benzinga Pro data.

Image via Shutterstock